Novavax (NVAX) Other Non-Current Assets (2010 - 2026)
Novavax (NVAX) posted quarterly Other Non-Current Assets of $16.0 million for Q1 2026, down 27.18% year-over-year from $21.9 million in Q1 2025, and down 81.77% quarter-over-quarter from $87.5 million in Q4 2025.
Novavax (NVAX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Novavax's Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 27.18% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 27.18% YoY), while the FY2025 annual figure was $87.5 million, up 264.62% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $16.0 million, down from $87.5 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $107.7 million in Q3 2025, with the low at $16.0 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $30.5 million (2023), against an average of $34.8 million.
- Peak annual rise in Other Non-Current Assets reached 1213.83% in 2022, while the deepest fall reached 54.6% in 2022.
- Novavax's Other Non-Current Assets stood at $28.5 million in 2022, then gained by 23.5% to $35.2 million in 2023, then tumbled by 31.74% to $24.0 million in 2024, then surged by 264.62% to $87.5 million in 2025, then plunged by 81.77% to $16.0 million in 2026.
- Business Quant data shows NVAX's Other Non-Current Assets at $16.0 million in Q1 2026, $87.5 million in Q4 2025, and $107.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 13.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.96 Mn |
| Mar 31, 2026 | 15.95 Mn |
| Dec 31, 2025 | 87.51 Mn |
| Sep 30, 2025 | 107.66 Mn |
| Jun 30, 2025 | 21.39 Mn |
| Mar 31, 2025 | 21.90 Mn |
| Dec 31, 2024 | 24.00 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 33.83 Mn |
| Mar 31, 2024 | 30.97 Mn |
| Dec 31, 2023 | 35.16 Mn |
| Sep 30, 2023 | 34.89 Mn |
| Jun 30, 2023 | 33.43 Mn |
| Mar 31, 2023 | 30.51 Mn |
| Dec 31, 2022 | 28.47 Mn |
| Sep 30, 2022 | 17.41 Mn |
| Jun 30, 2022 | 19.20 Mn |
| Mar 31, 2022 | 18.61 Mn |
| Dec 31, 2021 | 24.29 Mn |
| Sep 30, 2021 | 38.34 Mn |